Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas | Regeneron Pharmaceuticals Inc.
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron, consisting of a $50M upfront payment and $75M equity commitment, with up to approximately
Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas May 18, 2026 at 7:00 AM EDT PDF Version The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from Regeneron , consisting of a $50M upfront payment and $75M equity commitment, with up to approximately $2.2B in additional potential milestone payments plus tiered royalties TARRYTOWN, N.Y. , May 18, 2026 (GLOBE NEWSWI
Explore this link on the map →related reading
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Going Founder Mode On Cancer - by Elliot Hershbergcenturyofbio.com
- Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides | Nature Communicationsnature.com
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
- The Frontier in 2025renaissancephilanthropy.org
- Has pancreatic cancer met its match?worksinprogress.co
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- Hub-and-Spoke Biotechs: BridgeBio - by Elliot Hershbergcenturyofbio.com
- Sci-Hubsci-hub.box
- Treeline | Blogtreeline.bio